Abstract
In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 265-266 |
| Number of pages | 2 |
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 20 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 1987 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Oncology
- Cancer Research
Cite this
High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia. / Chan, Hon Y.; Meyers, Frederick J; Lewis, Jerry P.
In: Cancer Chemotherapy and Pharmacology, Vol. 20, No. 3, 09.1987, p. 265-266.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia
AU - Chan, Hon Y.
AU - Meyers, Frederick J
AU - Lewis, Jerry P.
PY - 1987/9
Y1 - 1987/9
N2 - In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.
AB - In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.
UR - http://www.scopus.com/inward/record.url?scp=0023627491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023627491&partnerID=8YFLogxK
U2 - 10.1007/BF00570500
DO - 10.1007/BF00570500
M3 - Article
C2 - 3677301
AN - SCOPUS:0023627491
VL - 20
SP - 265
EP - 266
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 3
ER -